1. Rowinsky EK, McGuire WP, Donehower RC: The current status of Taxol. Principles and practice of Gynecologic Oncology Updates. 1: 1–16, 1993
2. Holmes FA, Walters RS, Theriault RL, Forinan AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J NatI Cancer Inst 83: 1797–1805, 1991
3. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Curie V, Hudis CA, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Semin Oncol 11: 1943–1951, 1993
4. Seidman AD, Norton L, Reichman BS, Crown JP, Heelan R, Hakes TB, Lebwolh DE, Gilewski TA, Surbone A: Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 20: 40–45, 1993
5. Anand A: Paclitaxel in doxorubicin-resistant metastatic breast cancer patients. J NatI Cancer Inst 87: 1642, 1995 (letter)